FDA clears Investigational New Drug applications for Arcus Biosciences’ advanced prod
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that the U.S. Food and Drug Administration has cleared Investigational New Drug applications for the Company's two most advanced product candidates, AB928 and AB122.
More... |
All times are GMT -7. The time now is 02:38 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021